Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Modeling the Population Health Impact of Introducing a Modified Risk Tobacco Product into the U.S. Market.

Djurdjevic S, Lee PN, Weitkunat R, Sponsiello-Wang Z, Lüdicke F, Baker G.

Healthcare (Basel). 2018 May 16;6(2). pii: E47. doi: 10.3390/healthcare6020047.

2.

Tar level of cigarettes smoked and risk of smoking-related diseases.

Lee PN.

Inhal Toxicol. 2018 Jan;30(1):5-18. doi: 10.1080/08958378.2018.1443174. Epub 2018 Feb 28.

PMID:
29488428
3.

The relationship of snus use to diabetes and allied conditions.

Lee PN, Thornton AJ.

Regul Toxicol Pharmacol. 2017 Dec;91:86-92. doi: 10.1016/j.yrtph.2017.10.017. Epub 2017 Oct 20.

4.

Investigation into the risk of ultra-low tar cigarettes and lung cancer.

Lee PN, Fry JS, Hamling JS.

Regul Toxicol Pharmacol. 2017 Oct;89:112-117. doi: 10.1016/j.yrtph.2017.07.023. Epub 2017 Jul 25.

5.

Estimating the effect of differing assumptions on the population health impact of introducing a Reduced Risk Tobacco Product in the USA.

Lee PN, Fry JS, Hamling JF, Sponsiello-Wang Z, Baker G, Weitkunat R.

Regul Toxicol Pharmacol. 2017 Aug;88:192-213. doi: 10.1016/j.yrtph.2017.06.009. Epub 2017 Jun 24.

6.

The effect of time changes in diagnosing lung cancer type on its recorded distribution, with particular reference to adenocarcinoma.

Lee PN, Gosney JR.

Regul Toxicol Pharmacol. 2016 Nov;81:322-333. doi: 10.1016/j.yrtph.2016.09.019. Epub 2016 Sep 21. Review.

7.

Environmental Tobacco Smoke Exposure and Risk of Stroke in Never Smokers: An Updated Review with Meta-Analysis.

Lee PN, Thornton AJ, Forey BA, Hamling JS.

J Stroke Cerebrovasc Dis. 2017 Jan;26(1):204-216. doi: 10.1016/j.jstrokecerebrovasdis.2016.09.011. Epub 2016 Oct 17. Review.

8.

A systematic review of possible serious adverse health effects of nicotine replacement therapy.

Lee PN, Fariss MW.

Arch Toxicol. 2017 Apr;91(4):1565-1594. doi: 10.1007/s00204-016-1856-y. Epub 2016 Oct 3. Review.

9.

Environmental tobacco smoke exposure and risk of breast cancer in nonsmoking women. An updated review and meta-analysis.

Lee PN, Hamling JS.

Inhal Toxicol. 2016 Aug;28(10):431-54. doi: 10.1080/08958378.2016.1210701. Review.

10.

Epidemiological evidence on environmental tobacco smoke and cancers other than lung or breast.

Lee PN, Thornton AJ, Hamling JS.

Regul Toxicol Pharmacol. 2016 Oct;80:134-63. doi: 10.1016/j.yrtph.2016.06.012. Epub 2016 Jun 16. Review.

11.

Time trends in never smokers in the relative frequency of the different histological types of lung cancer, in particular adenocarcinoma.

Lee PN, Forey BA, Coombs KJ, Lipowicz PJ, Appleton S.

Regul Toxicol Pharmacol. 2016 Feb;74:12-22. doi: 10.1016/j.yrtph.2015.11.016. Epub 2015 Nov 27. Review.

13.

A novel approach to assess the population health impact of introducing a Modified Risk Tobacco Product.

Weitkunat R, Lee PN, Baker G, Sponsiello-Wang Z, González-Zuloeta Ladd AM, Lüdicke F.

Regul Toxicol Pharmacol. 2015 Jun;72(1):87-93. doi: 10.1016/j.yrtph.2015.03.011. Epub 2015 Mar 27.

14.

Is the shape of the decline in risk following quitting smoking similar for squamous cell carcinoma and adenocarcinoma of the lung? A quantitative review using the negative exponential model.

Fry JS, Lee PN, Forey BA, Coombs KJ.

Regul Toxicol Pharmacol. 2015 Jun;72(1):49-57. doi: 10.1016/j.yrtph.2015.02.010. Epub 2015 Feb 20.

15.

Smoking behaviour and compensation: a review of the literature with meta-analysis.

Scherer G, Lee PN.

Regul Toxicol Pharmacol. 2014 Dec;70(3):615-28. doi: 10.1016/j.yrtph.2014.09.008. Epub 2014 Sep 30. Review.

PMID:
25277253
16.

A review of the evidence on smoking bans and incidence of heart disease.

Lee PN, Fry JS, Forey BA.

Regul Toxicol Pharmacol. 2014 Oct;70(1):7-23. doi: 10.1016/j.yrtph.2014.06.014. Epub 2014 Jun 20. Review.

17.

Prevention of head louse infestation: a randomised, double-blind, cross-over study of a novel concept product, 1% 1,2-octanediol spray versus placebo.

Burgess IF, Brunton ER, French R, Burgess NA, Lee PN.

BMJ Open. 2014 May 30;4(5):e004634. doi: 10.1136/bmjopen-2013-004634.

18.

Estimating the decline in excess risk of chronic obstructive pulmonary disease following quitting smoking - a systematic review based on the negative exponential model.

Lee PN, Fry JS, Forey BA.

Regul Toxicol Pharmacol. 2014 Mar;68(2):231-9. doi: 10.1016/j.yrtph.2013.12.006. Epub 2013 Dec 19. Review.

19.

Epidemiological evidence relating snus to health--an updated review based on recent publications.

Lee PN.

Harm Reduct J. 2013 Dec 6;10:36. doi: 10.1186/1477-7517-10-36. Review.

20.

Estimating the decline in excess risk of cerebrovascular disease following quitting smoking--a systematic review based on the negative exponential model.

Lee PN, Fry JS, Thornton AJ.

Regul Toxicol Pharmacol. 2014 Feb;68(1):85-95. doi: 10.1016/j.yrtph.2013.11.013. Epub 2013 Nov 26. Review.

21.

The effect of quitting smoking on HDL-cholesterol - a review based on within-subject changes.

Forey BA, Fry JS, Lee PN, Thornton AJ, Coombs KJ.

Biomark Res. 2013 Sep 13;1(1):26. doi: 10.1186/2050-7771-1-26.

22.

Health risks related to dual use of cigarettes and snus - a systematic review.

Lee PN.

Regul Toxicol Pharmacol. 2014 Jun;69(1):125-34. doi: 10.1016/j.yrtph.2013.10.007. Epub 2013 Oct 31. Review.

23.

The effect of reducing the number of cigarettes smoked on risk of lung cancer, COPD, cardiovascular disease and FEV(1)--a review.

Lee PN.

Regul Toxicol Pharmacol. 2013 Dec;67(3):372-81. doi: 10.1016/j.yrtph.2013.08.016. Epub 2013 Sep 3. Review.

24.

How rapidly does the excess risk of lung cancer decline following quitting smoking? A quantitative review using the negative exponential model.

Fry JS, Lee PN, Forey BA, Coombs KJ.

Regul Toxicol Pharmacol. 2013 Oct;67(1):13-26. doi: 10.1016/j.yrtph.2013.06.001. Epub 2013 Jun 10.

25.
26.

The effect on health of switching from cigarettes to snus - a review.

Lee PN.

Regul Toxicol Pharmacol. 2013 Jun;66(1):1-5. doi: 10.1016/j.yrtph.2013.02.010. Epub 2013 Feb 26. Review.

27.

Systematic review with meta-analysis of the epidemiological evidence relating FEV1 decline to lung cancer risk.

Fry JS, Hamling JS, Lee PN.

BMC Cancer. 2012 Oct 27;12:498. doi: 10.1186/1471-2407-12-498. Review.

28.

Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer.

Lee PN, Forey BA, Coombs KJ.

BMC Cancer. 2012 Sep 3;12:385. doi: 10.1186/1471-2407-12-385. Review.

29.

Using the negative exponential distribution to quantitatively review the evidence on how rapidly the excess risk of ischaemic heart disease declines following quitting smoking.

Lee PN, Fry JS, Hamling JS.

Regul Toxicol Pharmacol. 2012 Oct;64(1):51-67. doi: 10.1016/j.yrtph.2012.06.009. Epub 2012 Jun 21. Review.

30.

1,2-Octanediol, a novel surfactant, for treating head louse infestation: identification of activity, formulation, and randomised, controlled trials.

Burgess IF, Lee PN, Kay K, Jones R, Brunton ER.

PLoS One. 2012;7(4):e35419. doi: 10.1371/journal.pone.0035419. Epub 2012 Apr 16.

31.

Reassessing the evidence relating smoking bans to heart disease.

Lee PN, Fry JS.

Regul Toxicol Pharmacol. 2011 Dec;61(3):318-31. doi: 10.1016/j.yrtph.2011.09.002. Epub 2011 Sep 17.

32.

Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema.

Forey BA, Thornton AJ, Lee PN.

BMC Pulm Med. 2011 Jun 14;11:36. doi: 10.1186/1471-2466-11-36. Review.

33.
34.

Summary of the epidemiological evidence relating snus to health.

Lee PN.

Regul Toxicol Pharmacol. 2011 Mar;59(2):197-214. doi: 10.1016/j.yrtph.2010.12.002. Epub 2010 Dec 14. Review.

PMID:
21163315
35.

Systematic review of the evidence relating FEV1 decline to giving up smoking.

Lee PN, Fry JS.

BMC Med. 2010 Dec 14;8:84. doi: 10.1186/1741-7015-8-84. Review.

36.

Hypotheses and fundamental study design characteristics for evaluating potential reduced-risk tobacco products. Part I: Heuristic.

Murrelle L, Coggins CR, Gennings C, Carchman RA, Carter WH Jr, Davies BD, Krauss MR, Lee PN, Schleef RR, Zedler BK, Heidbreder C.

Regul Toxicol Pharmacol. 2010 Jun;57(1):1-10. doi: 10.1016/j.yrtph.2009.12.002. Epub 2009 Dec 16.

PMID:
20018224
37.

Further considerations on the evaluation of potential reduced-risk tobacco products. Part II: Re-assessment of a heuristic using the CPS-II database.

Murrelle L, Coggins CR, Gennings C, Carchman RA, Lee PN, Zedler BK, Heidbreder C.

Regul Toxicol Pharmacol. 2010 Jun;57(1):11-7. doi: 10.1016/j.yrtph.2009.12.001. Epub 2009 Dec 16.

PMID:
20018223
39.

Systematic review of the relation between smokeless tobacco and cancer in Europe and North America.

Lee PN, Hamling J.

BMC Med. 2009 Jul 29;7:36. doi: 10.1186/1741-7015-7-36. Review.

40.

Does use of flue-cured rather than blended cigarettes affect international variation in mortality from lung cancer and COPD?

Lee PN, Forey BA, Fry JS, Hamling JS, Hamling JF, Sanders EB, Carchman RA.

Inhal Toxicol. 2009 Apr;21(5):404-30. doi: 10.1080/08958370802317737.

PMID:
19496695
41.

Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America.

Sponsiello-Wang Z, Weitkunat R, Lee PN.

BMC Cancer. 2008 Dec 1;8:356. doi: 10.1186/1471-2407-8-356.

42.

Systematic review of the relation between smokeless tobacco and non-neoplastic oral diseases in Europe and the United States.

Kallischnigg G, Weitkunat R, Lee PN.

BMC Oral Health. 2008 May 1;8:13. doi: 10.1186/1472-6831-8-13.

43.

Meta-analysis of the relation between European and American smokeless tobacco and oral cancer.

Weitkunat R, Sanders E, Lee PN.

BMC Public Health. 2007 Nov 15;7:334.

45.

Environmental tobacco smoke exposure and risk of stroke in nonsmokers: a review with meta-analysis.

Lee PN, Forey BA.

J Stroke Cerebrovasc Dis. 2006 Sep-Oct;15(5):190-201.

PMID:
17904075
46.

Circulatory disease and smokeless tobacco in Western populations: a review of the evidence.

Lee PN.

Int J Epidemiol. 2007 Aug;36(4):789-804. Epub 2007 Jun 25.

PMID:
17591642
47.

New edition of International Smoking Statistics.

Forey B, Lee PN.

Int J Epidemiol. 2007 Apr;36(2):471-2. Epub 2007 Apr 30. No abstract available.

PMID:
17470484
48.

Possible effects on smokers of cigarette mentholation: a review of the evidence relating to key research questions.

Werley MS, Coggins CR, Lee PN.

Regul Toxicol Pharmacol. 2007 Mar;47(2):189-203. Epub 2006 Nov 13. Review.

PMID:
17097785
49.
50.

The role of ammonia in the transfer of nicotine from tobacco to mainstream smoke.

Callicutt CH, Cox RH, Hsu F, Kinser RD, Laffoon SW, Lee PN, Podraza KF, Sanders EB, Seeman JI.

Regul Toxicol Pharmacol. 2006 Oct;46(1):1-17. Epub 2006 Jul 27.

PMID:
16875767

Supplemental Content

Loading ...
Support Center